Skip to main content
Evidence Snapshot

Delta-type opioid receptor

CHEMBL3222 SINGLE PROTEIN Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3222
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Delta-type opioid receptor as ChEMBL target CHEMBL3222, mapped to UniProt P32300. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Delta-type opioid receptor
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
ChEMBL target ID
CHEMBL3222
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P32300
Delta-type opioid receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Delta-type opioid receptor matters

As of 2026-09-13

Delta-type opioid receptor is reviewed as Delta-type opioid receptor (UniProt P32300); the current evidence base includes 11 approved drugs, 2054 compounds, and 565 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 2054 compounds, and 565 assays for this target. The dominant activity type is IC50. CHEMBL196774 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL196774 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Delta-type opioid receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P32300, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2054
Total Compounds
565
Total Assays
11
Approved Drugs
IC50: 1093.0, KI: 705.0, EC50: 54.0, KD: 165.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL196774
11.0 Kd
No preferred name
CHEMBL373192
11.0 Kd
No preferred name
CHEMBL607401
10.8 IC50
No preferred name
CHEMBL339320
10.8 IC50
No preferred name
CHEMBL129252
10.8 IC50

Approved Drugs

Structure Compound First Approval
NALFURAFINE
CHEMBL267495
2009
2009
NALTREXONE
CHEMBL19019
1984
MORPHINE
CHEMBL70
1984
NALOXONE
CHEMBL80
1971
FENTANYL
CHEMBL596
1968
1968
OXYMORPHONE
CHEMBL963
1959
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3222